The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? (Q38879975)

7 September 2017

1 reference

title

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? (English)

1 reference

7 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Annette T. Byrne

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Steven G Gray

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Markus Joerger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sinead Cuffe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

29 June 2016

1 reference

Expert Opinion on Therapeutic Targets

7 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1339-1356

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

Differentiation of effector CD4 T cell populations (*)

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

TH17 cells in development: an updated view of their molecular identity and genetic programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-23: A key cytokine in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Swords into plowshares: IL-23 repurposes tumor immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23 promotes tumour incidence and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The IL-23/IL-17 axis in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Cutting edge: A critical functional role for IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Th17 cells in cancer: the ultimate identity crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

T helper 17 cells play a critical pathogenic role in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Targeting histone deacetylases for the treatment of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Properties and origin of human Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Conserved intergenic elements and DNA methylation cooperate to regulate transcription at the il17 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

KDM6B Elicits Cell Apoptosis by Promoting Nuclear Translocation of FOXO1 in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Promotion of lung tumor growth by interleukin-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Effects of IL-17A on the occurrence of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Detection and significance of TregFoxP3(+) and Th17 cells in peripheral blood of non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The effect of proinflammatory cytokines on IL-17RA expression in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Therapeutic opportunities of the IL-22-IL-22R1 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin 22-producing CD4+ T cells in malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Association between Th17-related cytokines and risk of non-small cell lung cancer among patients with or without chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

GM-CSF: the secret weapon in the TH17 arsenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The role of STATs in transcriptional control and their impact on cellular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Secukinumab in plaque psoriasis--results of two phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A balance of interleukin-12 and -23 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Objective measurement and clinical significance of TILs in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

PDE4 inhibitors in COPD--a more selective approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

DAXAS and COPD Correlation with Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

A validated regulatory network for Th17 cell specification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Identification of SR2211: a potent synthetic RORγ-selective modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Inhibitory effects of azole-type fungicides on interleukin-17 gene expression via retinoic acid receptor-related orphan receptors α and γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Inhibiting RORγt/Th17 axis for autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Clinical improvement in psoriasis with specific targeting of interleukin-23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2016.1206891

10.1080/14728222.2016.1206891

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353429%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference